Alendronate is Not Indicated for Treatment of DISH
There is no established dose of alendronate for treating diffuse idiopathic skeletal hyperostosis (DISH) because DISH is not an indication for bisphosphonate therapy. DISH is a condition characterized by ossification and calcification of spinal ligaments and entheses—the opposite pathophysiologic process from osteoporosis, which bisphosphonates are designed to treat.
Why Alendronate Should Not Be Used for DISH
DISH involves excessive bone formation and ligamentous ossification, not bone loss. The pathophysiology includes:
- Ossification of the anterior longitudinal ligament creating characteristic "flowing" bone formation 1, 2
- Recent evidence suggests DISH may involve inflammatory processes that destroy original vertebral cortex and promote new bone formation 2
- Genetic studies link DISH to disorders of phosphate metabolism and loss of inhibitory pyrophosphate, which normally suppresses ectopic calcification 3
Bisphosphonates like alendronate work by inhibiting osteoclast-mediated bone resorption 4. They are FDA-approved for conditions involving bone loss, including:
- Postmenopausal osteoporosis (treatment: 10 mg daily or 70 mg weekly; prevention: 5 mg daily or 35 mg weekly) 5, 6
- Glucocorticoid-induced osteoporosis 7, 8, 6
- Osteoporosis in men 6
The Critical Distinction: DISH Patients May Have Concurrent Osteoporosis
Here's where clinical judgment becomes essential:
Patients with DISH can have coexisting low bone density, but this represents a separate pathologic process 9. A recent study found that DISH patients with T-scores ≤-1 actually had age-appropriate bone mineral density with normal bone metabolism markers (P1NP and TRACP-5b within normal ranges) 9. These patients did not require aggressive osteoporosis treatment 9.
When to Consider Bisphosphonates in DISH Patients
If a patient with DISH has documented osteoporosis (T-score ≤-2.5) or high fracture risk by FRAX criteria, then treat the osteoporosis according to standard guidelines:
- For osteoporosis treatment: Alendronate 10 mg daily or 70 mg weekly 5, 4, 6
- Ensure adequate calcium (1000-1200 mg daily) and vitamin D (800-1000 IU daily, adjusted to maintain 25(OH)D ≥30 ng/mL) 5, 10
- Must be taken fasting with full glass of water, remain upright 30 minutes 4
Important Caveats
DISH patients with low bone density are at increased risk for spine fractures 9, but this doesn't automatically warrant bisphosphonate therapy. The fracture risk in DISH relates to the rigid, ankylosed spine being vulnerable to trauma, not necessarily to osteoporotic bone quality.
Do not prescribe alendronate to treat the DISH itself—you would be giving an anti-resorptive medication for a condition characterized by excessive bone formation, which is physiologically counterintuitive and unsupported by evidence.
Contraindications to alendronate include: esophageal abnormalities, inability to remain upright 30 minutes, hypocalcemia, and severe renal impairment (GFR <35 mL/min for alendronate) 4, 6.